La Jolla (LJPC ) Lupus Blocks the overproduction of immune cells that attack the kidneys Status: Riquent has Fast Track designation, and the FDA issued an "approvable" letter in October, 2004, pending a further clinical trial. However, La Jolla warned on May 31 that it doesn't have the financial resources to continue that additional trial.